BioSpace News Archive

At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years

Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in haemophilia.

December 2, 2018
·
12 min read
Biotech Beach

Studies Offer Glimpses into the Future of Medicine

Significant advances in personalized medicine, predictive analytics, and use of big data

December 2, 2018
·
12 min read
Drug Development

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton’s Tyrosine Kinase Inhibitor to Date

With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients

December 2, 2018
·
15 min read
Drug Development

Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting

-Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma-

December 2, 2018
·
18 min read
Drug Development

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma

39 Percent of Patients in Ongoing Response Two Years after a Single Infusion of Yescarta in the ZUMA-1 Study; Median Overall Survival was Not Reached

December 2, 2018
·
11 min read
Business

NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting

More than One-Third of Drug-Resistant Epilepsy Patients Achieved ≥90% Seizure Reduction with the RNS System

December 2, 2018
·
4 min read
Drug Development

bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

bb21217 early safety profile consistent with CAR T platform therapies

December 2, 2018
·
10 min read
Drug Development

Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders

All five patients with inherited metabolic disorders (IMDs) treated with MGTA-456 in ongoing Phase 2 study met the primary endpoint of successful engraftment

December 2, 2018
·
9 min read
BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH

43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14)

December 2, 2018
·
5 min read
Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting

The combinations of melflufen and dexamethasone (dex) with either bortezomib or daratumumab in relapsed-refractory multiple myeloma (RRMM) patients are well tolerated

December 2, 2018
·
7 min read